Form 4: Vera Therapeutics CRO Granted Equity Awards

Vera Therapeutics' Chief Regulatory Officer, William D. Turner, was granted 25,000 restricted stock units and options to purchase 50,000 shares of Class A Common Stock.

Summary

• William D. Turner, Chief Regulatory Officer of Vera Therapeutics, Inc. (VERA), was granted equity awards on February 4, 2026.
• The awards include 25,000 Restricted Stock Units (RSUs) of Class A Common Stock.
• These RSUs will vest in four equal annual installments, with one-fourth vesting on each of February 20, 2027, 2028, 2029, and 2030, contingent on continuous service.
• Additionally, Mr. Turner was granted options to purchase 50,000 shares of Class A Common Stock with an exercise price of $42.74 per share.
• These stock options will vest monthly, with 1/48th of the shares vesting on March 4, 2026, and subsequent monthly vesting, also subject to continuous service.
• The stock options have an expiration date of February 3, 2036.
• Following these transactions, Mr. Turner beneficially owns 47,500 shares of Class A Common Stock directly and 50,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating continued commitment and incentivization of a key executive through long-term equity awards, aligning management interests with shareholder value.

Positives

• The grant of 25,000 Restricted Stock Units (RSUs) and options for 50,000 shares aligns the Chief Regulatory Officer's long-term interests with those of shareholders.
• Equity-based compensation incentivizes the executive to contribute to the company's sustained growth and stock price appreciation.

Negatives

• The awards are subject to multi-year vesting schedules, meaning the executive does not immediately realize the full value.
• The value of the equity awards is dependent on the future performance of Vera Therapeutics' stock price.

Risks

• The value of the granted RSUs and stock options is subject to market fluctuations of Vera Therapeutics' Class A Common Stock.
• Vesting of the awards is contingent upon the reporting person's continuous service, meaning forfeiture could occur if employment terminates before vesting dates.

Future Outlook

The vesting schedules for the RSUs and stock options extend through February 2030 and February 2036, respectively, indicating a long-term incentive structure for the Chief Regulatory Officer.

Industry Context

StockSavvy.ai notes that the grant of restricted stock units and stock options to key executives is a standard practice across the biotechnology and pharmaceutical industries. This compensation structure is designed to align the interests of management with long-term shareholder value creation, encouraging executives to focus on sustained company performance and growth.

Comparison to Industry Standards

• Equity grants, such as RSUs and stock options, are a common component of executive compensation packages in the biotechnology sector, comparable to practices at companies like Amgen, Gilead Sciences, and Biogen.
• The multi-year vesting schedules are typical for retaining talent and incentivizing long-term performance, aligning with global benchmarks for executive incentive plans.

Stakeholder Impact

• Shareholders: Potentially positive, as executive compensation is tied to long-term company performance, aligning interests.
• Employees (specifically the reporting person): Receives significant long-term equity compensation, incentivizing continued service and performance.

Next Steps

• Vesting of 1/48th of the stock options monthly, commencing March 4, 2026.
• Vesting of one-fourth of the Restricted Stock Units annually, commencing February 20, 2027.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a key executive, which is a standard compensation practice. It does not provide new information on the company's operational or financial performance that would warrant a change in investment recommendation.

Keywords

Vera Therapeutics, VERA, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Executive Compensation, William D. Turner, Chief Regulatory Officer